Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07574164

Closed-loop TMS for Tremor

Closed-loop TMS for Tremor — Recruiting • Non-phase study • Neurology • NCT07574164.

📅 07 May 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07574164
Start
2024-01-01
Completion
2026-01-01
ClinicaliQ Trial Snapshot
  • Closed-loop TMS for Tremor — Recruiting • Non-phase study • Neurology • NCT07574164.
  • Phase-locked brain stimulation may reduce tremor in essential tremor and Parkinson's disease patients when timed to suppress tremor cycles.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study investigates the potential of phase-locked transcranial magnetic stimulation (TMS) as a non-invasive intervention for tremor in patients with Essential Tremor (ET) and Parkinson's Disease (PD). Tremor is a prevalent symptom that significantly impacts physical function and social participation. ET affects approximately 1% of the global population and worsens with age, while PD tremor is often less responsive to conventional dopaminergic therapy. Current treatments, including oral medications (propranolol, primidone), anticholinergics, and deep brain stimulation (DBS), are either limited by efficacy, side effects, or invasiveness. These challenges highlight the need…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
AI may speed up search for drugs to treat brain conditions
Neurology · BBC Health · 22 May 2026
AI tools are being developed to accelerate drug discovery for neurological conditions including motor neurone disease, potentially reducing development timelines This approach…
View brief →
Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Clinical Brief
My daughter has childhood dementia and may not live past 16
Neurology · BBC Health · 01 Apr 2026
Key Clinical Takeaways Childhood dementia represents a group of rare progressive neurodegenerative disorders with devastating outcomes—Sophia's case illustrates the severe functional decline…
View brief →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
Former nurse dies amid dementia drug shortages
Neurology · BBC Health · 02 Sep 2026
Dementia medication shortages are affecting patient care and outcomes, with documented cases of treatment interruptions leading to clinical deterioration Family advocacy and…
View brief →
Clinical Brief
Families hit by long waits for dementia diagnosis
Neurology · BBC Health · 02 Sep 2026
Dementia diagnosis delays are widespread, with patients experiencing waits of months to years, creating prolonged uncertainty for families during a critical period…
View brief →